Santhera Wins Marketing Approval for Ataxia Therapy
Posted on: Thursday, 24 July 2008, 12:01 CDT
Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia.
Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena. Launch of Catena is anticipated by the end of October 2008.
In clinical studies submitted to Health Canada as part of the approval process, Catena showed statistically and clinically relevant improvements in Friedreich's Ataxia patients, as measured by Activities of Daily Living scores as well as cardiac and neurological functions.
The approved product labeling allows for the treatment of symptoms of Friedreich's Ataxia. Two doses are approved: a starting dose of 450mg/day for patients below 45kg body weight and 900mg/day for patients above 45kg body weight whereby treating physicians have an option to dose up to 1,350mg/day for patients below 45kg body weight and up to 2,250mg/day for patients of more than 45 kg body weight if needed.
Under the conditions of the notice of compliance, Santhera has agreed to submit additional data from its ongoing Phase III clinical trial in the US to confirm the efficacy of the therapy.
MJ Roach, Santhera's general manager for North America, said: "Canada's marketing authorization provides an excellent foundation to establish a medical and marketing platform in North America for the treatment of rare neuromuscular diseases in general and for Friedreich's Ataxia in particular.
"The Canadian market will also provide valuable insights for launching the product in the US, once the ongoing clinical trial is completed and the product is approved."
Source: Datamonitor
Related Articles
- Xoft Receives Health Canada Regulatory Approval for the Axxent(R) Electronic Brachytherapy System
- Santhera Receives First Product Approval: Health Canada Approves Catena(R) for Treatment of Friedreich's Ataxia
- ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
- ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
- ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
- Genzyme Receives Approval to Market Elaprase in Japan
- Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
- First Patient Enrolled in SONOMA Post-Market Approval Study of Boston Scientific NexStent(R) Carotid Stent System and FilterWire EZ(TM) Embolic Protection Device
- St. Jude Medical Announces FDA Approval and U.S. Market Launch of the Merlin Patient Care System; New Programmer Brings 21st Century Advances to Patient Follow-Ups
- Xyrem(R) (Sodium Oxybate) Receives FDA Approval for the Treatment of Excessive Daytime Sleepiness in Patients With Narcolepsy
 |
 |
User Comments (0)
RSS Feeds